Britain and America have concluded a landmark bilateral deal that will ensure no levies on UK drug exports going into the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to raise expenditure on drugs through the National Health Service (NHS). This commitment secures that tariffs on these vital exports will be held at zero for a duration of the next three years.
This development comes after previous statements to dramatically increase duties on branded drug imports, with increases discussed reaching 100%.
"This deal with the United Kingdom bolsters the international landscape for new treatments and establishes much-needed fairness to American-British pharmaceutical trade," a statement said.
Trade Impact
Pharmaceuticals represent one of the Britain's most significant export categories to the United States, which is easily the biggest market for major UK drugmakers.
Statistics indicate that in the 12 months leading up to the third quarter, the UK sold pharmaceutical products valued at billions to the US. This value made up nearly one-fifth of total UK exports in that timeframe.
"This guarantee safeguards jobs, boosts capital expenditure and facilitates the UK to emerge as a international leader for life sciences," a government official remarked.
Detailed NHS Changes
The deal includes several notable pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a target to raise total NHS spending on drugs from 0.3% of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to control costs will be limited at fifteen percent. In the past, rebates were more than 20%.
Industry Background
The deal comes amid a protracted tension between the sector and the British authorities over spending levels and approval rates.
These tensions were exacerbated by arguments that US consumers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been halted or scrapped, while major investments have been directed toward projects in the United States.
One official acknowledged that the NHS had to spend more on medicines, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.
